Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BBI-940

Small molecule · Degrader of kinesin · developed by Boundless Bio

Phase 1 Most advanced trial (none active)
BOLD Developer
1 Registered trials

What is BBI-940?

BBI-940 is an orally bioavailable small molecule degrader of kinesin. It degrades and inhibits kinesin, which is needed for segregating extrachromosomal DNA during mitosis, causing mis-segregation and cell cycle arrest in ecDNA-enabled cancer cells. It is being studied in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
kinesin
Mechanism
Degrader of kinesin
Pathways
extrachromosomal DNA segregation during mitosis, cell cycle arrest
Therapy area
Oncology
Developer
Boundless Bio, Inc. (BOLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07408089 Phase 1 Breast Cancer Terminated BOLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerBreast CancerMetastatic Breast Cancer

More from Boundless Bio

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLD page.

Follow BOLD, the company behind BBI-940

See BOLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.